May occur for MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease patients when tapering to a lower dose of steroidsA type of medication typically given intraveneously or orally. For myelin oligodendrocyte glycoprotein antibody disease (MOGAD) it is used as an immunosuppressant and anti-inflammatory to reduce disease activity and inflammation. In adults, it is sometimes used in high doses for acute attacks. In some adult patients, it may be used for 1-2 months after an acute attack to avoid a rapid onset of relapse. Higher doses (>10mg/day) are not recommended for an extended period of time but lower doses (<=10mg/day) may be used in some patients longer term. In children, it may be used after treatment of an acute attack, but it is not recommended long-term due to the profound effects of chronic steroids on a child's health. Use of oral prednisone as a maintenance therapy in relapsing pediatric MOGAD patients is discouraged due to side effects in developing children, and other therapies such as monthly immune globulin are suggested. (To understand relapsing during steroid tapering, see Steroid Dependency) causing recurrance of symptoms and may cause a relapseWhen you present to your doctor or hospital with new or worsening central nervous system symptoms. Generally, if your symptoms gradually worsen over 24-48 hours, there is heightened concern of a relapse. (Also referred to as a flare by the myelin oligodendrocyte glycoproten antibody disease (MOGAD) community). of new disease activity.
Steroid Dependency
Related Posts
The MOG Project Featured by Johns Hopkins Medicine
The MOGA type of protein involved in cell adhesion. Present throughout myelin sheaths. Project is honored to be featured by Johns Hopkins Medicine in a recent article highlighting advances in understanding myelin oligodendrocyte glycoprotein antibody diseaseOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease
The MOG Project Awards 2025 Research Grants
The MOG Project’s Research for Rare program has awarded our 2025 MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease global research grants: the Apollo Grant and the Accelerator Grant. These grants are
Eliza’s Story: Weaving Emotional Support into the Fabric of Rare Disease Advocacy
Hello everyone, My name is Eliza, and at the age of 34, I was diagnosed with MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease – a disease I had never heard of
